Log in

OTCMKTS:HDII - Hypertension Diagnostics Stock Price, Forecast & News

0.00 (0.00 %)
(As of 04/1/2020 03:34 AM ET)
Today's Range
Now: $0.02
50-Day Range
MA: $0.01
52-Week Range
Now: $0.02
Volume4.86 million shs
Average Volume5.41 million shs
Market Capitalization$1.46 million
P/E RatioN/A
Dividend YieldN/A
Hypertension Diagnostics, Inc. designs, develops, manufactures, and markets proprietary noninvasive medical devices that detect subtle changes in the elasticity of arteries in the United States and internationally. It offers CVProfilor, which allows a physician to non-invasively assess the elasticity of small and large arteries, of which small artery elasticity is the earliest and sensitive marker of cardiovascular disease. The company offers CVProfilor DO-2020, which provides a patient's arterial elasticity indices used in the assessment for underlying vascular disease; CVProfilor MD-3000 that offers a sensitive and specific guide to the presence of blood vessel disease; and HD/PulseWave CR-2000 research cardiovascular profiling system, which provides researchers and scientists with a non-invasive means to assess arterial elasticity in support of human research in various areas. Its products collect 30 seconds of blood pressure waveform data, perform an analysis of the digitized blood pressure waveforms, and generate a CVProfile report that contains information on blood pressure, heart rate, pulse pressure, body surface area, body mass index, and C1-large and C2-small artery elasticity indices. The company sells its products to primary care physicians, cardiologists, health care professionals, trained medical personnel, research investigators at academic medical research centers, government institutes, cardiovascular specialists, and pharmaceutical firms. It markets its products through a representative organization in the United States. Hypertension Diagnostics, Inc. was founded in 1988 and is based in Minnetonka, Minnesota.
Read More

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolOTCMKTS:HDII



Sales & Book Value

Annual Sales$3.68 million
Book Value($58.84) per share



Market Cap$1.46 million
Next Earnings DateN/A
OptionableNot Optionable

Receive HDII News and Ratings via Email

Sign-up to receive the latest news and ratings for HDII and its competitors with MarketBeat's FREE daily newsletter.

Hypertension Diagnostics (OTCMKTS:HDII) Frequently Asked Questions

How has Hypertension Diagnostics' stock been impacted by COVID-19 (Coronavirus)?

Hypertension Diagnostics' stock was trading at $0.0176 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, HDII stock has increased by 2.3% and is now trading at $0.0180. View which stocks have been mosted impacted by Coronavirus.

Has Hypertension Diagnostics been receiving favorable news coverage?

Headlines about HDII stock have trended very negative on Wednesday, InfoTrie Sentiment reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Hypertension Diagnostics earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future. View the latest news aboutHypertension Diagnostics.

Who are some of Hypertension Diagnostics' key competitors?

What other stocks do shareholders of Hypertension Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hypertension Diagnostics investors own include Integrated Cannabis (ICNAF), Hemp (HEMP), GASTAR EXPL INC/SH (GST), Zynerba Pharmaceuticals (ZYNE), Tonix Pharmaceuticals (TNXP), NXT-ID (NXTD), New Age Beverages (NBEV), Genocea Biosciences (GNCA), Cypress Semiconductor (CY) and Celldex Therapeutics (CLDX).

Who are Hypertension Diagnostics' key executives?

Hypertension Diagnostics' management team includes the following people:
  • Mr. Kenneth W. Brimmer, CEO, Pres, CFO & Director (Age 64)
  • Mr. Joseph D'Albero, Exec.
  • Mr. Maury Taylor, Exec. Director

What is Hypertension Diagnostics' stock symbol?

Hypertension Diagnostics trades on the OTCMKTS under the ticker symbol "HDII."

How do I buy shares of Hypertension Diagnostics?

Shares of HDII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Hypertension Diagnostics' stock price today?

One share of HDII stock can currently be purchased for approximately $0.02.

How big of a company is Hypertension Diagnostics?

Hypertension Diagnostics has a market capitalization of $1.46 million and generates $3.68 million in revenue each year. Hypertension Diagnostics employs 3 workers across the globe. View additional information about Hypertension Diagnostics.

What is Hypertension Diagnostics' official website?

The official website for Hypertension Diagnostics is http://www.hypertensiondiagnostics.com/.

How can I contact Hypertension Diagnostics?

Hypertension Diagnostics' mailing address is 550 Highway 7 East Unit 316, Minnesota MN, L4B 3Z4. The company can be reached via phone at 404-449-6151.

MarketBeat Community Rating for Hypertension Diagnostics (OTCMKTS HDII)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  56 (Vote Outperform)
Underperform Votes:  50 (Vote Underperform)
Total Votes:  106
MarketBeat's community ratings are surveys of what our community members think about Hypertension Diagnostics and other stocks. Vote "Outperform" if you believe HDII will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HDII will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel